Analyst firms · Robert W. Baird · QGEN

Robert W. Baird QGEN price target and rating history

Qiagen N.V. (QGEN) · Health Care

Robert W. Baird rates Qiagen N.V. (QGEN) Outperform with a $43 price target, as of its latest action on Apr 29, 2026. It has published 3 rating actions on QGEN since September 2023, including 1 upgrade and 1 downgrade. Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Robert W. Baird's $43 is 7% below that.

Current rating
Outperform
Price target
$43
Median target, all firms
$46.25
Actions on QGEN
3

Robert W. Baird price target on QGEN

$50$46$42202420252026
Robert W. Baird price target on QGEN, each point a stated target, September 2023 to April 2026.

Every Robert W. Baird rating on QGEN

How other firms rate QGEN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$55Oct 6, 2026
UBSNeutral$47Sep 9, 2026
BerenbergHold$45.50Jul 14, 2026
Kepler CheuvreuxHold$38.60Jun 25, 2026
Morgan StanleyOverweight$42Jun 23, 2026
Robert W. BairdOutperform$43Apr 29, 2026
Deutsche BankBuy$54Mar 13, 2026
CitigroupNeutral$50Dec 11, 2025

Questions about Robert W. Baird and QGEN

What is Robert W. Baird's price target for QGEN?
Robert W. Baird's latest stated price target for Qiagen N.V. (QGEN) is $43, from its action on Apr 29, 2026.
What is Robert W. Baird's rating on QGEN?
Robert W. Baird rates QGEN Outperform, a bullish rating, as of Apr 29, 2026.
When did Robert W. Baird last change its view on QGEN?
On Apr 29, 2026, Robert W. Baird upgrades to Outperform from Neutral, price target $43.
How does Robert W. Baird's QGEN target compare with other analysts?
Across 8 firms with a QGEN price target in the last 12 months, the median target is $46.25. Robert W. Baird's $43 is 7% below that.

More QGEN rating histories

All Robert W. Baird ratingsQGEN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.